Lallemand Health Solutions has announced the fourth edition of the Mind, Mood & Microbes International conference on Microbiome-Gut-Brain axis
As a co-founding partner, Lallemand Health Solutions proudly presents the fourth edition of the Mind, Mood & Microbes International conference on Microbiome-Gut-Brain axis, which will take place in Amsterdam, the Netherlands, on 10-11 May 2023.
The event will gather an unmatched line-up of leading scientists, healthcare professionals, and industry partners from complementary fields to share new developments and findings about microorganisms' impact on the brain-gut axis and mental wellness.
The gut microbiota, by its ability to modulate the brain development and function, has become a primary target to influence, not only mood and behaviour, but to address conditions such as anxiety and depression, and brain-related conditions, including Parkinson’s disease, Alzheimer’s disease, schizophrenia, and autism. One of the current challenges is the translation of research insights into the clinical context.
Lallemand Health Solutions is a pioneer in the microbiome-gut-brain axis science. Our first publication dates back over 85 years ago! In the 2000s, we have launched the first-ever clinical trial, where we studied the positive effects of a probiotic intervention on the reduction of psychological occasional stress in healthy adults
- Lucie Lingrand, Product Manager, responsible for the Mental health portfolio at Lallemand
This year's programme includes presentations on neurodevelopment, neurological and psychiatric disorders, biological pathways, and molecular mechanisms. Download the full agenda here.
“Lallemand Health Solutions is a pioneer in the microbiome-gut-brain axis science. Our first publication dates back over 85 years ago! In the 2000s, we have launched the first-ever clinical trial, where we studied the positive effects of a probiotic intervention on the reduction of psychological occasional stress in healthy adults. In total, our flagship psychobiotic formula Cerebiome (registered trademark) has been documented in seven clinical studies [including studies on depressive patients showing beneficial outcomes] and over ten pre-clinical studies, leading to better understand eight mechanisms of action of this unique psychobiotic on the gut-brain axis”, summarises Lucie Lingrand, Product Manager, responsible for the Mental health portfolio at Lallemand Health Solutions. “Our ongoing investments and commitment in research have led to explore how probiotics can be beneficial in innovative fields beyond stress and depression and we hope to see significant, life-changing results in the near future."
During the event, Apsen Farmaceutica, Lallemand Health Solutions commercial partner in Brazil, will share insights about their latest study demonstrating that Cerebiome exerts a positive influence on the gut microbiota of individuals with mild anxiety.
It is not too late to register! Mind, Mood & Microbes organisers invite gastroenterologists, physiologists, neuroscientists and other microbiota-gut-brain axis passionate, to participate in this global gathering of experts to move science forward!
Mind, Mood & Microbes is a global event, held every two years, bringing together leading scientists, healthcare professionals, and industry partners from diverse backgrounds to share progress in the field of the microbiota-gut-brain axis and accelerate the translation of pre-clinical into clinical research breakthroughs and into professional and clinical practice. More info and registration here
The major R&D challenges focus on the development and characterisation of the effects of first and new generation probiotics on human health. Lallemand’s Health Solutions division has integrated platforms for preclinical, clinical, galenic and bioprocess development, and a dedicated R&D team of 40 people, notably managing some twenty clinical trials on five continents. The division’s production plants operate according to Good Manufacturing Practices (GMP), including one site holding a manufacturing authorisation according to GMP for medicinal products for human use (Saint-Simon, France).
Cerebiome (a proprietary combination of L. helveticus Rosell (registered trademark) -52 and B. longum Rosell-175) is the most documented psychobiotic in the world, with significant results showing it helps alleviate the physical and psychological symptoms of stress and feelings of anxiety. CEREBIOME is the first and only probiotic with authority-approved health claims on the gut-brain axis.